- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
RTI Biologics Inc
+ Add to WatchlistRTIX:US
4.3000 USD 0.0700 1.60%As of 20:10:00 ET on 05/21/2013.
Snapshot for RTI Biologics Inc (RTIX)
| Open: | 4.4000 | Day's Range: | 4.2900 - 4.4000 | Volume: | 152,799 |
|---|---|---|---|---|---|
| Previous Close: | 4.3700 | 52wk Range: | 3.3500 - 5.1100 | 1-Yr Rtn: | +20.45% |
Key Statistics for RTIX
| Current P/E Ratio (ttm) | 25.2941 |
|---|---|
| Estimated P/E(12/2013) | 23.7569 |
| Relative P/E vs. SPX | 1.5515 |
| Earnings Per Share (USD) (ttm) | 0.1700 |
| Est. EPS (USD) (12/2013) | 0.1810 |
| Est. PEG Ratio | 1.5838 |
| Market Cap (M USD) | 241.96 |
| Shares Outstanding (M) | 56.27 |
| 30 Day Average Volume | 258,552 |
| Price/Book (mrq) | 1.3025 |
| Price/Sale (ttm) | 1.3761 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/31/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for RTIX
Company Profile & Key Executives for RTIX
RTI Biologics, Inc. processes human and animal musculoskeletal tissues in producing allograft and xenograft implants. The Company's products are used by surgeons to repair bone and other tissue defects, such as vertebrae repair, musculoskeletal reconstruction, fracture repair, joint repair and reconstruction for sports medicine injuries.
| Dean Howard BergyChairman | Brian K HutchisonPresident/CEO |
| Robert P JordheimExec VP/CFO | Thomas F RoseExec VP/Chief Ops Ofcr/Secy |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
RTIX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page